1University of Maryland; 2Futures Group International; 3CDC; 4USAID

Slides:



Advertisements
Similar presentations
Client-centered HIV testing and counseling as a strategy for scaling up access to HIV prevention and care services Mongare J 1, Odhiambo F 1, Ojoo S 1,
Advertisements

Absorption, Retention and Empowerment
The effect of changes in Kenya HIV guidelines on proportion of patients on ART and patient characteristics at initiation in Lumumba Health Centre, Western.
Risk factors and true outcomes of children lost to follow-up from antiretroviral therapy in Lilongwe, Malawi C. Ardura Gracia, H. Tweya, C Feldacker, S.
Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
Retention across the continuum of care in a cohort of HIV infected children in rural India G. Alvarez-Uria RDT Hospital, Department of Infectious Diseases,
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Primary Healthcare Facilities Deliver More Effective Antiretroviral Therapy: An Evaluation in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
AIDS Turning the Tide Together IAS Satellite: Where the Tide Will Turn: How is Community Level Participation Most Effective in Turning the Tide?
Effects of patient tracing on estimates of lost to follow-up, mortality and retention in antiretroviral therapy programs in low-middle income countries:
Decentralization of HIV care and treatment services in Central Province, Kenya: Adult patient characteristics and outcomes Presenting author: William Reidy,
Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Management and Development for Health (MDH)
Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo- controlled trial in Rakai, Uganda Steven J.
Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.
The Positive Predictive Value of World Health Organization (WHO) Immunologic Criteria for Treatment Failure in a Public Health Antiretroviral Delivery.
Factors Associated with Survival in HIV-Infected African Patients on Antiretroviral Therapy: The Impact of a Sampling-Based Approach to Address Losses.
Community-based Adherence Clubs improve outcomes for stable ART patients: Outcomes from Cape Town, South Africa Anna Grimsrud 1, Maia Lesosky 1,2, Cathy.
Providing Treatment, Restoring Hope Program Updates Dr. Robb Sheneberger, MD University of Maryland School of Medicine Track 1.0 Implementers Meeting Dar.
Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
Failure to Initiate ART, Loss to Follow-up and Mortality among HIV-infected Patients during the pre-ART period in Uganda Elvin H. Geng 1, Winnie Muyindike.
Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.
Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.
Mövenpick Royal Palm Hotel Dar es Salaam, Tanzania August 4-6, 2009 The 7th Annual Track 1.0 ART Program Meeting.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.
WAD SYMPOSIUM 2014 ART Adherence and Retention: MDH Experience Eric Aris Management and Development for Health 29 th November 2014 NJOMBE.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Successfully enrolled in HIV Care but not linked to timely Treatment: Poor retention and Monitoring of Pre-ART patients who are not yet eligible for ART.
Improving Patients Retention in Antiretroviral Treatment Programs: The experience of ARV Programs in Côte d’Ivoire Eugène MESSOU, MD, PhD CePReF- Aconda.
Retention in an antiretroviral program in the Democratic Republic of Congo Kalenga Lucien Koole Olivier Menten Joris Kiumbu Modeste Robin Ryder Mukumbi.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
Boston University Slideshow Title Goes Here District Prevalence of Unsuppressed HIV in South African Women: Monitoring Programme Performance and Progress.
MASIVUKENI: A Multimedia ART Initiation and Adherence Intervention for Resource-Limited Settings Robert H. Remien, Claude A. Mellins, Reuben Robbins, Hetta.
Boston University Slideshow Title Goes Here Eliminating CD4 thresholds in South Africa will not lead to large increases in persons receiving ART without.
Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,
Early survival and clinic retention among high risk HIV-infected patients initiating cART in a pilot Express Care system compared to Routine Care in Western.
The CQUIN Learning Network: Partnering to Advance Differentiated Care
Factors associated with loss to follow up in a primary healthcare clinic practicing test and treat Authors: Julius Kiwanuka1,2, Noah Kiwanuka3, Flavia.
PRESENTED AT THE 9TH IAS CONFERENCE ON HIV SCIENCE - PARIS, FRANCE
Men are absent across the HIV continuum of care in a rural area of southern Mozambique Laura Fuente-Soro, Elisa Lopez-Varela, Orvalho Augusto , Charfudin.
Earlier treatment and lower mortality in infants Initiating ART at
Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.
2Ministry of Health and Child Care, AIDS & TB Unit, Harare, Zimbabwe
Participants 18year old+
Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital
L.F. Jefferys1, J. Hector1, M.A. Hobbins2, J. Ehmer2, N. Anderegg3
First roll out of universal access to antiretroviral therapy under routine program conditions in rural Swaziland. Authors: Bernhard Kerschberger (1), Sikhathele.
Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case control study Nebiyu Mesfin, MD.
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
Utilizing research as an opportunity to strengthen
A COLLABORATIVE APPROACH TO ESTABLISH PREDICTORS
Juan Gonzalez Perez AIDS Healthcare Foundation
Dr. Velephi Okello, Principal Investigator, MaxART Trial
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Knowing your epidemic and knowing your response – maximising routinely collected data to measure and monitor HIV epidemics in sub-Saharan Africa Monitoring.
Extended ART Initiation Criteria Can Be Implemented Successfully in Rural South Africa Sarah Jane Steele1, Gemma Arellano2, Tom Ellman3, Amir Shroufi1,
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Towards the last 90% of the 90:90:90 strategy: A review of viral suppression rates in a HIV program in Central and Eastern Kenya Dr Moses Kitheka,
Management and Development for Health (MDH)
Conflicting of interest disclosure: None
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Godwin N. Mugo (MBChB, MPH)1 Victor Ogoti (BscIT)1
Stakeholder engagement and research utilization: Insights from Namibia
Update on global progress in ART
Why Quality Matters in ART Programs
Treatment Outcome among patients on ART in Southern Tanzania: Does Time of ART initiation Matter?
Presentation transcript:

1University of Maryland; 2Futures Group International; 3CDC; 4USAID Sustained improvement in antiretroviral treatment outcomes in a large cohort in sub-Saharan Africa: bucking the trend Authors: Ojoo SA1, Nganga L2, Odhiambo FA1, Wandina D1, Ooko H2, Ngethe R2, Nganga LW3, Odek J4, Burrows L2, Redfield R1 1University of Maryland; 2Futures Group International; 3CDC; 4USAID

Baggaley, 2012; Boulle, 2010; Nglazi, 2011; Introduction Kenya has successfully expanded access to ART, with over 600,000 patients on ART by December 2012. Scale-up has occurred within an acute care health system, with suboptimal capacity for chronic care Published reports demonstrate increased rates of loss to follow-up (LTFU) with each calendar year of patient enrolment Attrition may minimize gains anticipated with expanded treatment coverage. Globally 9.7 m patients were on ART by Dec 2012; Kenya contributed over 600k to this figure. Remarkably this expansion of services has occurred within a HC system designed to support acute episodic care, with suboptimal capacity for chronic care services. Published reports from SSA indicate that with HIV service expansion, patient retention in care may be a growing challenge, with increased rates of loss to follow-up (LTFU) with each calendar year of patient enrolment observed. Baggaley et al. 2012; World Health Organization 2012; Granich et al. 2009; Lancet 373, 48–57; Boulle et al. 2010; AIDS 24, 563–572. Nglazi et al. 2011 Journal of Acquired Immune Deficiency Syndromes 56, e1–e8. Baggaley, 2012; Boulle, 2010; Nglazi, 2011;

Background: AIDSRelief Program A robust chronic care model developed Community-facility linkage Prioritized patient case-management Standardized patient encounter tools Electronic HMIS (IQCare) Capacity for data-driven process & patient care improvement AIDSRelief Kenya Sites: This presentation is based on data from the AR program, PEPFAR funded program implemented in 10 countries including Kenya, where 29 facilities were supported to provide HIV prevention, care and treatment services. From the outset a robust chronic care model was defined for implementation and comprised CBTS, patient case management recognizing that patient vulnerability is dynamic, standardized patient encounter tools, EMR, DDIU/QI. The degree to which the model was implemented was fairly uniform across sites. CRS was the prime with the University of Maryland responsible for the the technical strategy.

Objective To describe the yearly trends in retention and attrition rates of patients on ART in the AIDSRelief Kenya program.

Methods Retrospective analysis of de-identified data of adults age >15 years, enrolled on ART from 2004-2012 Patients missing DOB, transferred-out were excluded. Year of ART start was main explanatory variable, and 12-month retention the main end-point Rates were derived from K-M survival probability estimates Cox proportional hazards used to determine effect of year of ART start, adjusted for baseline characteristics Wald confidence limits used for all time-event analyses Retrospective analysis of de-identified data of adult patients enrolled on ART in this program. Rates were derived from Kaplan-Meier (K-M) survival probability estimates with 95% confidence limits calculated around the survival probabilities. Patients in the AR program did not have access to routine VL testing, thus as part of program quality reviews patient level outcomes were assessed periodically based on viral load measurement in a sample of patients. Cox proportional hazards models were used to determine effect of year of ART initiation adjusted for relevant baseline characteristics. Wald confidence limits were used for all time-to-event (K-M and multivariate) analyses. Jan-Mar 2011, HIV RNA measurements (Cavidi ExaVir®Load) carried out in a random sample of 1,114 patients on ART for >12m [median (IQR) duration on ART 52 (34.5-64) months] On-treatment suppression (HIV RNA<200 copies/ml) rate calculated

Results Data was analyzed for 64,259 adults, followed up on ART, for a median duration of 31 (IQR 11-53) months. 68% of patients female; median baseline age 37 (IQR 30-44) years 68% of patients were from rural facilities Median baseline CD4 count was 204 (IQR 101-303) cells/mm3 On-treatment viral RNA suppression rate in 1,114 patients was 93.7% Viral suppression rate based on the cavidi platform and a cut off of 200 c/ml

Location of Point of Service Baseline characteristics by year of ART start Location of Point of Service WHO clinical stage at ART start Baseline median CD4 count % with CD4 < 50 stable at 8-10% This is predominantly rural program. cohort entering care became healthier over time as shown in this slide. There was improvement in documentation with significant decline in undocumented bWHO Stage, indicated in red, from 45% in 2004/05 to 2% in 2012. Median baseline CD4 count increase from 150 (IQR 73-255) cells/mm3 in 2004/05 to 254 (IQR 130-341) cells/mm3 in 2012. Documentation of the CD4 count at baseline also increased from 56% in 2004 to 78% in 2012. % of patients with CD4 < 50 remained stable at 8-10%. Documented opportunistic infections at ART Initiation declined significantly over time, from 44% in 2004/05 to 15% in 2012.

12-month cohort retention and attrition rates ART Start Cohort Year Number of Patients Starting ART Retention (%) 95% CI Mortality (%) LTFU (%) 2004/05 4,081 83.8 82.6-84.9 11.6 10.6-12.6 7.1 6.3-8.0 2006 5,710 87.0 86.1-87.9 8.5 7.8-9.3 5.8 2007 7,259 84.8 83.9-85.6 8.3 7.6-8.9 7.3 6.6-7.9 2008 8,880 83.5 82.7-85.1 7.6 7.0-8.2 9.3 8.7-10.0 2009 10,213 84.4 83.7-85.1 7.7 7.2-8.2 8.0 7.4-8.5 2010 10,616 86.4 85.7-87.0 6.7-7.6 6.5 6.0-7.0 2011 8,804 88.8 88.1-89.0 6.1 5.7-6.7 4.1 3.7-4.5 2012 9,696 93.0 92.1-93.8 4.5 3.8-5.3 2.2 1.8-2.6

Loss to follow up over time by year of ART start 2008 – poor rates as a result of an election gone bad. Duration (in months) on ART

Mortality over time by year of ART start Mortality fell from 11.6(10.6,12.6) to 4.5(3.8,5.3)% Duration (in months) on ART

Retention over time by year of ART start Duration (in months) on ART

CQI/DDIU Guided Interventions (THPE077) 12m probability of retention, mortality & LTFU by ART initiation cohort CQI/DDIU Guided Interventions (THPE077) Looking at the cohorts of patients starting ART in each calendar year, the overall retention rate increased from 83.8% (95% CI 82.6-84.9) to 93% (95% CI 92.1-93.8) Mortality rate decreased from 11.6% (95% CI 10.6-12.6) to 4.5% (95% CI 3.8-5.3) LTFU rate declined from 7.1% (95% CI 6.3-8.0) to 2.2% (95% CI 1.8-2.6)

Conclusion 12-month probability of retention improved significantly during 8 years of patient follow-up in this large cohort (185,512 patient years of follow up) A significant and sustained reduction in LTFU rates in successive calendar years was observed; inconsistent with several publications As would be expected, there was a significant reduction in mortality rates over the 8-year period Degree of reduction in mortality - published

Conclusion These outcomes, increasing retention, as a result of declining mortality & LTFU rates, as well as high viral suppression, suggest that programmatic conditions for optimal population impact of expanded ART coverage can be achieved in resource-limited settings. Degree of reduction in mortality - published

Acknowledgement PEPFAR-CDC/HRSA Facilities, staff and patients University of Maryland Futures Group International Catholic Relief Services Catholic Medical Missions Board Robert Redfield Lucy Nganga Francesca Odhiambo Hesbon Ooko Daniel Wandina Lucy Wanjiku Nganga James Odek